Pancreatic cancer will soon be the second leading cause of cancer deaths in the United States. Ben Stanger, MD, PhD and Ursina Teitelbaum, MD, share the goals of current clinical research in pancreatic cancer at the Penn Pancreatic Cancer Research Center of the Abramson Cancer Center, including liquid biopsies, immunotherapy and precision approaches—and review the current expanding portfolio of treatments available today at Penn Medicine.

Related Links:

Enrolling Clinical Trials: Rucaparib for the Treatment of Pancreatic Cancer
Enrolling Clinical Trials: Combination Chemotherapy / Immunotherapy for Patients With Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma